⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7426229 | 0.73 | — | — | |
| SCHEMBL1164718 | 0.70 | — | — | |
| Ammonia Solution, Strong SCHEMBL6782155 | 0.63 | — | — | |
| SCHEMBL23270410 | 0.62 | — | — | |
| SCHEMBL892033 | 0.62 | — | — | |
| SCHEMBL14759415 | 0.61 | — | — | |
| SCHEMBL705721 | 0.61 | — | — | |
| SCHEMBL177873 | 0.61 | — | — | |
| SCHEMBL155313 | 0.61 | — | — | |
| SCHEMBL1819721 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815892-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2014-08-26 | — | — | US | claimed |
| US-8569334-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-10-29 | — | — | US | claimed |
| US-20130197046-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-08-01 | — | — | US | claimed |
| EP-2569281-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | Affectis Pharmaceuticals AG (DE) | 2013-03-20 | — | — | EP | claimed |
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-03-07 | — | — | US | claimed |
| WO-2012163792-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-12-06 | — | — | WO | claimed |
| US-20120302597-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-11-29 | — | — | US | claimed |
| US-8232290-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-07-31 | — | — | US | claimed |
| EP-2243772-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-01-18 | — | — | EP | claimed |
| WO-2011141194-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-11-17 | — | — | WO | claimed |
| EP-2105164-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-01-12 | — | — | EP | claimed |
| EP-2243772-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2010-10-27 | — | — | EP | claimed |
| WO-2010118921-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | WO | claimed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | claimed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| US-20090312366-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-12-17 | — | — | US | claimed |
| WO-2009118175-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2009-10-01 | — | — | WO | claimed |
| EP-2105164-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2009-09-30 | — | — | EP | claimed |
| EP-1851199-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | Aventis Pharmaceuticals, Inc. (US) | 2007-11-07 | — | — | EP | claimed |
| WO-2006086705-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-17 | — | — | WO | claimed |